Laurie R Braun1, Meghan N Feldpausch2, Natalia Czerwonka2, Martin Torriani3, Steven K Grinspoon2, Takara L Stanley4. 1. Program in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States; Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. 2. Program in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. 3. Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. 4. Program in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States; Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. Electronic address: tstanley@partners.org.
Abstract
OBJECTIVE: Fibroblast growth factor 21 (FGF21) ameliorates steatohepatitis but is increased in humans with fatty liver, potentially due to compensatory mechanisms and/or FGF21 resistance. Further, animal models suggest that GH increases serum FGF21. Tesamorelin, a growth hormone releasing hormone agonist, reduces liver fat in HIV-infected individuals. The objectives of this study were to investigate changes in FGF21 during tesamorelin treatment, to elucide the interplay between FGF21, GH augmentation, and liver fat reduction in humans. METHODS:50 HIV-infected men and women with increased abdominal adiposity participated in this randomized, placebo-controlled trial of tesamorelin, 2mg vs. identical placebo daily for six months. Fasting laboratory measures, liver fat by 1H-magnetic resonance spectroscopy, and visceral adipose tissue (VAT) by computed tomography were obtained. Euglycemic hyperinsulinemic clamp was performed in a randomly selected subset. RESULTS: At baseline, serum log10 FGF21 was significantly associated with log10 liver fat (r=0.32, p=0.03). Log10 FGF21 tended to decrease in the tesamorelin group compared to placebo (p=0.06). Among the entire cohort, reductions in FGF21 were significantly associated with reductions in liver fat (ρ=0.41, p=0.01), log10 gamma glutamyl tran speptidase (GGT, r=0.40, p=0.009), and FIB4 index (r=0.37, p=0.02). CONCLUSIONS: In HIV-infected individuals, FGF21 is significantly positively associated with liver fat. FGF21 decreases in association with reductions in liver fat, GGT, and FIB4, suggesting that FGF21 is upregulated in the context of steatosis and steatohepatitis and is reduced when these conditions improve. Moreover, these data suggest that tesamorelin improves liver fat via pathways other than increasing serum FGF21. TRIAL REGISTRATION: clinicaltrials.govNCT01263717.
RCT Entities:
OBJECTIVE:Fibroblast growth factor 21 (FGF21) ameliorates steatohepatitis but is increased in humans with fatty liver, potentially due to compensatory mechanisms and/or FGF21 resistance. Further, animal models suggest that GH increases serum FGF21. Tesamorelin, a growth hormone releasing hormone agonist, reduces liver fat in HIV-infected individuals. The objectives of this study were to investigate changes in FGF21 during tesamorelin treatment, to elucide the interplay between FGF21, GH augmentation, and liver fat reduction in humans. METHODS: 50 HIV-infectedmen and women with increased abdominal adiposity participated in this randomized, placebo-controlled trial of tesamorelin, 2mg vs. identical placebo daily for six months. Fasting laboratory measures, liver fat by 1H-magnetic resonance spectroscopy, and visceral adipose tissue (VAT) by computed tomography were obtained. Euglycemic hyperinsulinemic clamp was performed in a randomly selected subset. RESULTS: At baseline, serum log10 FGF21 was significantly associated with log10 liver fat (r=0.32, p=0.03). Log10 FGF21 tended to decrease in the tesamorelin group compared to placebo (p=0.06). Among the entire cohort, reductions in FGF21 were significantly associated with reductions in liver fat (ρ=0.41, p=0.01), log10 gamma glutamyl tran speptidase (GGT, r=0.40, p=0.009), and FIB4 index (r=0.37, p=0.02). CONCLUSIONS: In HIV-infected individuals, FGF21 is significantly positively associated with liver fat. FGF21 decreases in association with reductions in liver fat, GGT, and FIB4, suggesting that FGF21 is upregulated in the context of steatosis and steatohepatitis and is reduced when these conditions improve. Moreover, these data suggest that tesamorelin improves liver fat via pathways other than increasing serum FGF21. TRIAL REGISTRATION: clinicaltrials.govNCT01263717.
Authors: Jean-Marc Schwarz; Kathleen Mulligan; Jeongae Lee; Joan C Lo; Michael Wen; Mustafa A Noor; Carl Grunfeld; Morris Schambelan Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Ffolliott M Fisher; Patricia C Chui; Imad A Nasser; Yury Popov; Jeremy C Cunniff; Thomas Lundasen; Alexei Kharitonenkov; Detlef Schuppan; Jeffrey S Flier; Eleftheria Maratos-Flier Journal: Gastroenterology Date: 2014-07-30 Impact factor: 22.682
Authors: Javier Gómez-Ambrosi; José M Gallego-Escuredo; Victoria Catalán; Amaia Rodríguez; Pere Domingo; Rafael Moncada; Víctor Valentí; Javier Salvador; Marta Giralt; Francesc Villarroya; Gema Frühbeck Journal: Clin Nutr Date: 2016-05-04 Impact factor: 7.324
Authors: João Paulo G Camporez; François R Jornayvaz; Max C Petersen; Dominik Pesta; Blas A Guigni; Julie Serr; Dongyan Zhang; Mario Kahn; Varman T Samuel; Michael J Jurczak; Gerald I Shulman Journal: Endocrinology Date: 2013-06-13 Impact factor: 4.736
Authors: J Lundberg; C Höybye; T Krusenstjerna-Hafstrøm; H A Bina; A Kharitonenkov; B Angelin; M Rudling Journal: J Intern Med Date: 2013-07-24 Impact factor: 8.989
Authors: Alberto O Chavez; Marjorie Molina-Carrion; Muhammad A Abdul-Ghani; Franco Folli; Ralph A Defronzo; Devjit Tripathy Journal: Diabetes Care Date: 2009-06-01 Impact factor: 19.112
Authors: Allison Ross Eckard; Heather Y Hughes; Nancy L Hagood; Mary A O'Riordan; Danielle Labbato; Julia C Kosco; Sarah E Scott; Grace A McComsey Journal: J Acquir Immune Defic Syndr Date: 2020-04-15 Impact factor: 3.771